Cited by 4,233Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsRadiation Therapy and Dosimetry

The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index.

Nanoparticle therapeutics: an emerging treatment modality for cancer

Davis, Mark E., Chen, Zhuo, Shin, Dong M.·2008·Nature Reviews Drug Discovery

Abstract

Nanoparticles--particles in the size range 1-100 nm--are emerging as a class of therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumours and active cellular uptake. Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While large numbers of preclinical studies have been published, the emphasis here is placed on preclinical and clinical studies that are likely to affect clinical investigations and their implications for advancing the treatment of patients with cancer.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd2614

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 108 references

2 of the 108 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Kurtzberg, J., Moore, J. O. Scudiery, D. & Franklin, A. A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukaemias. Proc. Am. Assoc. Cancer Res. 29, 213 (1988).
  2. Socinski, M. & Ramalingham, S. XYOTAX in NSCLC and other solid tumors. Emerging evidence on biological differences between men and women: is gender-specific therapy warranted? Chemotherapy Foundation web site [online], (2005).
  3. Vasey, P. et al. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin) first member of a new class of chemotherapeutics agents: drug–polymer conjugates. Clin. Cancer Res. 5, 83–94 (1999).

Cited by

Sorted by citations

Items 301–400 of 1,023

Metadata

Authors
Davis, M. E., Chen, Z., & Shin, D. M.
Affiliations
  • California Institute of Technology (US)
  • Emory University (US)
Corresponding author
Davis, Mark E.
Venue
Nature Reviews Drug Discovery
Published
2008-09
Volume
7
Issue
9
Pages
771-782
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2082511916
Cited by
4,233
References
108
Citations by year
2026: 68 · 2025: 134 · 2024: 165 · 2023: 143 · 2022: 171 · 2021: 217 · 2020: 224 · 2019: 260 · 2018: 316 · 2017: 340 · 2016: 364 · 2015: 383 · 2014: 385 · 2013: 332 · 2012: 268
FWCI
7.10
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • CaltechAUTHORS (California Institute of Technology) (submittedVersion)
Funders
National Cancer Institute (U54CA119338)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Keywords
nanotherapeutics, cancer therapy, nanomedicine, targeted drug delivery, tumor localization, cellular uptake, clinical translation, clinical trials, anticancer agents, adverse drug reactions
MeSH terms
Animals, Antineoplastic Agents, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Drug Delivery Systems, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review